[17] L. Liu, J. Greger, H. Shi, Y. Liu, J. Greshock, R. Annan, W. Halsey, G.M. Sathe, A.-M. Martin, T.M.
Gilmer, Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL,
Cancer Research, 69 (2009) 6871-6878.
[18] Q. Wang, H. Quan, J. Zhao, C. Xie, L. Wang, L. Lou, RON confers lapatinib resistance in HER2-positive
breast cancer cells, Cancer Letters, 340 (2013) 43-50.
[19] B.N. Rexer, A.J.L. Ham, C. Rinehart, S. Hill, N. de Matos Granja-Ingram, A.M. Gonzalez-Angulo, G.B.
Mills, B. Dave, J.C. Chang, D.C. Liebler, C.L. Arteaga, Phosphoproteomic mass spectrometry profiling links
Src family kinases to escape from HER2 tyrosine kinase inhibition, Oncogene, 30 (2011) 4163-4174.
[20] P.J.A. Eichhorn, M. Gili, M. Scaltriti, V. Serra, M. Guzman, W. Nijkamp, R.L. Beijersbergen, V. Valero,
J. Seoane, R. Bernards, J. Baselga, Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib
Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235, Cancer
Research, 68 (2008) 9221-9230.
[21] N. Suzuki, T. Shiota, F. Watanabe, N. Haga, T. Murashi, T. Ohara, K. Matsuo, N. Oomori, H. Yari, K.
Dohi, M. Inoue, M. Iguchi, J. Sentou, T. Wada, Synthesis and evaluation of novel pyrimidine-based dual
EGFR/Her-2 inhibitors, Bioorg Med Chem Lett, 21 (2011) 1601-1606.
[22] H. Mastalerz, M. Chang, P. Chen, P. Dextraze, B.E. Fink, A. Gavai, B. Goyal, W.C. Han, W. Johnson, D.
Langley, F.Y. Lee, P. Marathe, A. Mathur, S. Oppenheimer, E. Ruediger, J. Tarrant, J.S. Tokarski, G.D. Vite,
D.M. Vyas, H. Wong, T.W. Wong, H. Zhang, G. Zhang, New C-5 substituted pyrrolotriazine dual inhibitors
of EGFR and HER2 protein tyrosine kinases, Bioorg Med Chem Lett, 17 (2007) 2036-2042.
[23] Y. Kawakita, K. Miwa, M. Seto, H. Banno, Y. Ohta, T. Tamura, T. Yusa, H. Miki, H. Kamiguchi, Y. Ikeda,
T. Tanaka, K. Kamiyama, T. Ishikawa, Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual
inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-
tumor efficacy, Bioorg Med Chem, 20 (2012) 6171-6180.
[24] T. Ishikawa, M. Seto, H. Banno, Y. Kawakita, M. Oorui, T. Taniguchi, Y. Ohta, T. Tamura, A.
Nakayama, H. Miki, H. Kamiguchi, T. Tanaka, N. Habuka, S. Sogabe, J. Yano, K. Aertgeerts, K. Kamiyama,
Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth
factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold, J Med Chem, 54
(2011) 8030-8050.
[25] R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll,
M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, P.S. Shenkin, Glide: a new approach for rapid, accurate
docking and scoring. 1. Method and assessment of docking accuracy, J Med Chem, 47 (2004) 1739-1749.
[26] T.A. Halgren, R.B. Murphy, R.A. Friesner, H.S. Beard, L.L. Frye, W.T. Pollard, J.L. Banks, Glide: a new
approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening, J Med
Chem, 47 (2004) 1750-1759.
[27] P.A. Schwartz, P. Kuzmic, J. Solowiej, S. Bergqvist, B. Bolanos, C. Almaden, A. Nagata, K. Ryan, J.
Feng, D. Dalvie, J.C. Kath, M. Xu, R. Wani, B.W. Murray, Covalent EGFR inhibitor analysis reveals
importance of reversible interactions to potency and mechanisms of drug resistance, Proceedings of the
National Academy of Sciences, 111 (2014) 173-178.
[28] A. Wissner, T.S. Mansour, The development of HKI-272 and related compounds for the treatment of
cancer, Archiv der Pharmazie, 341 (2008) 465-477.
[29] D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, L.R. Chirieac, R.F. Padera, G.I. Shapiro, A.
Baum, F. Himmelsbach, W.J. Rettig, M. Meyerson, F. Solca, H. Greulich, K.K. Wong, BIBW2992, an
irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene, 27 (2008)
4702-4711.
[30] T. Suzuki, A. Fujii, J. Ohya, Y. Amano, Y. Kitano, D. Abe, H. Nakamura, Pharmacological
characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase
inhibitor, Cancer Sci, 98 (2007) 1977-1984.